Multiprofile Hospital For Active Treatment St. Ivan Rilski Gorna Oriahovitsa EOOD

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis7 trials
• Crohn's disease6 trials
• Fatty liver disease (MASLD/MASH)3 trials
• Asthma2 trials
• Stroke2 trials
• Chronic kidney disease1 trial
• Liver cirrhosis1 trial

Phase

• Phase 210 trials
• Phase 38 trials

Status

• Recruiting6 trials
• Active, not recruiting5 trials
• Completed5 trials
• Not yet recruiting2 trials

Lead sponsor

• Hoffmann-La Roche4 trials
• GlaxoSmithKline2 trials
• Sanofi-Aventis Recherche & Developpement2 trials
• Spyre Therapeutics, Inc.2 trials
• AstraZeneca1 trial
• and 7 more

Running trials

• Enrolling by invitation

  Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

  NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source

• Recruiting

  A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease

  2025-522001-38-00· Phase 2· Mirador Therapeutics Inc.· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma

  NCT07301736· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· Phase 3· GlaxoSmithKline· Source

• Recruiting

  A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  NCT07012395· Phase 2· Spyre Therapeutics, Inc.· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

  NCT06748053· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06589986· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Phase IIa Study Evaluating AZD7798 in Crohn's Disease

  NCT06450197· Phase 2· AstraZeneca· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

  NCT06419374· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

  NCT06318169· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

  NCT05668013· Phase 2· Teva Branded Pharmaceutical Products R&D LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)3 recruiting
• Ulcerative colitis3 recruiting
• Crohn's disease1 recruiting
• Liver cirrhosis1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative colitis

  NCT07222189· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease.

  NCT06637631· Phase 2· Sanofi-Aventis Recherche & Developpement· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

  NCT05499130· Phase 2· Teva Branded Pharmaceutical Products R&D, Inc.· Source

• Completed

  A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

  NCT05047263· Phase 3· Bayer· Source